Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Conditions

• Waldenstrom's Macroglobulinemia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bortezomib — DRUG
  Once weekly for 3 weeks
• Rituximab — DRUG
  Intravenously once a week for the first and fourth weeks of a cycle

Study Details

In this study, we are trying to find out if the combination of these two drugs is effective in treating Waldenstrom's macroglobulinemia (WM). The combination of these two drugs has not been studied for patients with relapsed or refractory macroglobulinemia. The U.S. Food and Drug Administration (FDA) has approved bortezomib for the treatment of multiple myeloma, a cancer that is closely related to Waldenstrom's macroglobulinemia.

Key Dates

Start date

Aug 30, 2006

Status verified

Oct 2020

Primary completion

Oct 9, 2015

Completion

Oct 9, 2015

Study Design

Enrollment

63 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: bortezomib and rituximab
  bortezomib and rituximab

Primary Outcome Measure

Overall Response Rate of Bortezomib and Rituximab (VR) in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (WM) [ Time Frame: 2 Years ]

Locations (1)

Find similar trials in Boston, MA